[{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"INO-3106","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"INO-3107","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Beijing Advaccine Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Inovio Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Inovio Pharmaceuticals \/ Inovio Pharmaceuticals"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"VGX-3100","moa":"HPV-16\/HPV-18 protein","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"VGX-3100","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ INOVIO","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ INOVIO"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"International Vaccine Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ International Vaccine Institute","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ International Vaccine Institute"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 DNA Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Inovio Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"INO-3107","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Defense Advanced Research Projects Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"DNA-encoded monoclonal antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Inovio Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Defense Advanced Research Projects Agency","highestDevelopmentStatusID":"4","companyTruncated":"Inovio Pharmaceuticals \/ Defense Advanced Research Projects Agency"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"ApolloBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"VGX-3100","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ ApolloBio","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pharmaceuticals \/ ApolloBio"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"GLS-5300","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"VGX-3100","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"INO-4500","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"ApolloBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"VGX-3100","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ ApolloBio","highestDevelopmentStatusID":"10","companyTruncated":"Inovio Pharmaceuticals \/ ApolloBio"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Qiagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"VGX-3100","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ INOVIO","highestDevelopmentStatusID":"10","companyTruncated":"Inovio Pharmaceuticals \/ INOVIO"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"INO-4802","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"INO-4500","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Beijing Advaccine Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Advaccine Biopharmaceuticals Suzhou Co., Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Advaccine Biopharmaceuticals Suzhou Co., Ltd"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"VGX-3100","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"GuardRX","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Ebola DNA vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ GuardRX","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ GuardRX"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Termination","leadProduct":"Durvalumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ MedImmune","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pharmaceuticals \/ MedImmune"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Richter-Helm BioLogics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Richter-Helm BioLogics","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Richter-Helm BioLogics"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"INO-3107","moa":"HPV6\/HPV11","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"INO-4500","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"INO-4201","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"INO-3107","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"INO-3107","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"INO-3107","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"INO-3107","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"INO-3107","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"INO-3112","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Coherus Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Inovio Pharmaceuticals \/ Coherus Biosciences"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"INO-3107","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"INO-3107","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Inovio Pharmaceuticals \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Inovio Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target